Abstract
The radiochemical 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG), a positron emitter, is taken up preferentially by malignant tumors with high metabolic rates. This concentration of 18F-FDG in the tumor permits diagnosis and staging by positron emission tomography but also may represent a means of targeting radiotherapy. In this study, we determined the effect of a higher dose of 18F-FDG on tumor growth in a mouse model. The effect of 18F-FDG on the growth and viability of 3 tumor cell lines was determined in vitro. Primary tumor growth and metastasis of B16/BL6 melanoma cells were determined in C57BL/6 mice injected with 5 mCi doses of 18F-FDG (2/3 doses). 18F-FDG was cytostatic for all 3 cell lines at the lowest dose tested. It significantly reduced the growth of primary tumors, by 89% at day 19 postinoculation, and also almost totally inhibited the appearance of lung metastases after intravenous inoculation of the same cells. 18F-FDG proved to be an effective radiotherapeutic agent in this model. The possible problems associated with the accumulation of this radiochemical at other sites besides the tumor must be addressed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
